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context issues. Many of these same policies are now being applied across
Canada to address access to cancer services during the COVID-19
pandemic.
Conclusion: A 20-year case study of the Ontario RT access crisis in the
1990s, and the post-crisis periods, offer many useful learnings that can be
applied to current policy challenges in access to care due to the ongoing
pandemic.
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Purpose/Objective(s): The COVID-19 pandemic largely suspended conventional in-person scientiﬁc meetings because of the risk of disease spread.
In the era of vaccination and social distancing practices, meetings have slowly
begun to return to in-person formats. We surveyed attendees and potential
attendees of two United States oncology meetings to identify rates of mixing
behavior and the subsequent rate of self-reported COVID-19 infection.
Materials/Methods: We collected reported social mixing behavior and
COVID-19 positivity of actual and potential in-person oncology meeting
attendees of the American Society of Clinical Oncology (ASCO) Quality
Care Symposium in Boston, Massachusetts on September 24-25, 2021, and
the American Society for Radiation Oncology (ASTRO) Annual Meeting in
Chicago, Illinois on October 24-27, 2021 via survey. Participants were identiﬁed through publicly available meeting materials and targeted via email
when possible. Recruitment was also conducted through Twitter and a radiation oncology newsletter, as well as an anonymous link made available to
emailed recruits, with sharing encouraged. In-person respondents to the later
ASTRO survey who had attended the ASCO meeting were excluded from the
analysis. Statistical signiﬁcance was determined using Fisher’s exact test for
rates of COVID-19 positivity and the chi-squared statistic for differences in
group characteristics, with a cutoff for statistical signiﬁcance p<0.05.
Results: Response rates from attendees with publicly available emails were
27.4% for the ASCO meeting and 14.3% for the ASTRO meeting. The
ASCO survey produced 94 responses, with 48 responding as in-person
attendees. The ASTRO survey produced 370 responses, with 267 responding as in-person attendees. Across both meetings, 3 of 308 (1.0%) of in-person attendees versus 2 of 141 (1.4%) of non-attendees tested positive for
COVID-19 (p=0.65). Among in-person attendees, there were similar low
COVID-19 positivity rates among those spending more (>20) vs less (≤20)
hours attending live sessions (2.2% vs 0%, p=0.25) and between those who
went to indoor social events vs those who did not during the meeting periods (0.8% vs 1.9%, p=0.44). Attendees largely felt that they would feel comfortable attending additional in-person meetings after experiencing the
ASCO (87.5%) or ASTRO (91.9%) meetings and that mask compliance was
good or excellent at the ASCO (100%) and ASTRO (94.6%) meetings.
Conclusion: This study indicates that in-person meetings do not seem to
be contributing to high rates of new COVID-19 infections in the setting of
mask mandates, vaccine mandates, and decreased room capacity allowances. The rate of self-reported COVID-19 infection of both in-person attendees and non-attendees was very low and the meetings were successful at
creating an environment where participants felt safe. These ﬁndings support the possibility of a path forward for at least partially in-person conferences as new variants emerge and COVID-19 becomes endemic.

Purpose/Objective(s): Machine learning (ML), a type of artiﬁcial
intelligence (AI) technology that uses a data-driven approach for pattern recognition, has been shown by numerous research studies to be
beneﬁcial for tasks across healthcare. In this study, we aim to characterize the commercial availability of oncology-speciﬁc AI/ML applications in the clinic by performing a detailed analysis of such devices
that were approved/cleared by the US Food and Drug Administration
(FDA).
Materials/Methods: A list of 343 AI/ML-enabled medical devices that
were approved or cleared by the FDA up to June 2021 was published
by the agency, and this list was used to construct the initial database
for our study. The publicly available FDA approval letters for these
devices were independently reviewed by two research assistants, and a
device was classiﬁed as oncology-speciﬁc if its primary intended use is
related to assisting the diagnosis or treatment of oncologic pathologies.
For oncology-speciﬁc devices, additional details on device characteristics, FDA regulatory process, and approved indications were obtained.
A basic descriptive statistical analysis was performed on the aggregated
data.
Results: Fifty-two (15.2%) of the 343 AI/ML-enabled medical devices were
classiﬁed as oncology-speciﬁc. The growth of the oncologic-speciﬁc devices
sharply rose since the mid-2010s, with 49 (94.2%) approved in 2016 or
after. Fifty (96.2%) devices were cleared by the 510(k) premarket notiﬁcation pathway, and, except for one class III device, the remaining 51 devices
were considered as class II by the FDA. All but one device was considered
Software as a Medical Device (SaMD). Thirty-six (69.2%) devices were
intended for diagnostic purposes, of which 24 (66.7%), 9 (14.3%), 1 (6.3%),
1 (6.3%), and 1 (6.3%) was for the detection of breast cancer, lung cancer,
prostate cancer, thyroid cancer, and bone cancer, respectively. The 16 devices intended for therapeutic purposes were all related to radiotherapy: 15
are for radiation treatment planning (all included organ auto-segmentation
as the main function), and 1 is a linear accelerator equipped with AI/ML
algorithms.
Conclusion: Our results showed a rapid increase of oncology-speciﬁc,
FDA-approved, AI/ML-enabled medical devices since 2016. Further study
is needed to assess the impact made by these devices on the delivery of
oncology care.
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